Clinical and epidemiological features of Chryseobacterium indologenes infections: Analysisof 215 cases

Journal of Microbiology, Immunology and Infection

Volumn 46, Issue 6, 2013, Pages 425-432

  Chen, Fu Lun ^a,b   Wang, Giueng Chueng ^a,b   Teng, Sing On ^a,b   Ou, Tsong Yih ^a,b   Yu, Fang Lan ^a,b   Lee, Wen Sen ^a,b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Chryseobacterium indologenes; Colistin; Tigecycline; Trimethoprim sulfamethoxazole

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZTREONAM; CARBAPENEM; CEFEPIME; CEFOPERAZONE PLUS SULBACTAM; CEFOTAXIME; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; DAPTOMYCIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE;

ACINETOBACTER BAUMANNII; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIUM CULTURE; BACTERIUM ISOLATE; CAUSE OF DEATH; CHRYSEOBACTERIUM INDOLOGENES; CHRYSEOBACTERIUM INDOLOGENES INFECTION; CLINICAL FEATURE; COMORBIDITY; CORRELATIONAL STUDY; DRUG USE; FEMALE; FLAVOBACTERIACEAE INFECTION; HUMAN; IN VITRO STUDY; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MINIMUM INHIBITORY CONCENTRATION; MIXED INFECTION; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PNEUMONIA; PREVALENCE; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; SEX DIFFERENCE;

CHRYSEOBACTERIUM INDOLOGENES; COLISTIN; TIGECYCLINE; TRIMETHOPRIM-SULFAMETHOXAZOLE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; CHRYSEOBACTERIUM; COLISTIN; DRUG PRESCRIPTIONS; DRUG RESISTANCE, BACTERIAL; FEMALE; FLAVOBACTERIACEAE INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MINOCYCLINE; PNEUMONIA, BACTERIAL; PREVALENCE; SURVIVAL ANALYSIS;

EID: 84889663753     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2012.08.007     Document Type: Article

References (27)

1. Hsueh P.R., Hsiue T.R., Wu J.J., Teng L.J., Ho S.W., Hsieh W.C., et al. Flavobacterium indologenes bacteremia: clinical and microbiological characteristics. Clin Infect Dis 1996, 23:550-555.
2. Siegman-Igra Y., Schwartz D., Soferman G., Konforti N. Flavobacterium group IIb bacteremia: report of a case and review of Flavobacterium infections. Med Microbiol Immunol 1987, 176:103-111.
3. Bonten M.J., van Tiel F.H., van der Geest S., Smeets H.G., Stobberingh E.E., Gaillard C.A. Topical antimicrobial prophylaxis of nosocomial pneumonia in mechanically ventilated patients. Microbiological observations. Infection 1993, 21:137-139.
4. Bagely D.H., Alexander J.C., Gill V.J., Dolin R., Ketcham A.S. Late Flavobacterium species meningitis after craniofacial exenteration. Arch Intern Med 1976, 136:229-231.
5. Stamm W.E., Colella J.J., Anderson R.L., Dixon R.E. Indwelling arterial catheters as a source of nosocomial bacteremia: an outbreak caused by Flavobacterium species. N Engl J Med 1975, 292:1099-1102.
6. Sudharani V., Asiya, Saxena N.K. Chryseobacterium indologenes bacteremia in a preterm baby. Indian J Med Microbiol 2011, 29:196-198.
7. Lin Y.T., Jeng Y.Y., Lin M.L., Yu K.W., Wang F.D., Liu C.Y. Clinical and microbiological characteristics of Chryseobacterium indologenes bacteremia. J Microbiol Immunol Infect 2010, 43:498-505.
8. Brown R.B., Phillips D., Barker M.J., Pieczarka R., Sands M., Teres D. Outbreak of nosocomial Flavobacterium meningosepticum respiratory infections associated with use of aerosolized polymyxin B. Am J Infect Control 1989, 17:121-125.
9. Lo W.T., Lin W.J., Chiueh T.S., Lee S.Y., Wang C.C., Lu J.J. Changing trends in antimicrobial resistance of major bacterial pathogens, 1985-2005: a study from a medical center in northern Taiwan. J Microbiol Immunol Infect 2011, 44:131-138.
10. Kirby J.T., Sader H.S., Walsh T.R., Jones R.N. Antimicrobial susceptibility and epidemiology of a worldwide collection of Chryseobacterium spp.: report from the SENTRY Antimicrobial Surveillance Program. J Clin Microbiol 1997-2001, 2004(42):445-448.
11. Matsumoto T., Nagata M., Ishimine N., Kawasaki K., Yamauchi K., Hidaka E., et al. Characterization of CIA-1, an Ambler class A extended-spectrum β-lactamase from Chryseobacterium indologenes. Antimicrob Agents Chemother 2012, 56:588-590.
12. Bellais S., Poirel L., Leotard S., Naas T., Nordmann P. Genetic diversity of carbapenem-hydrolyzing metallo-beta-lactamases from Chryseobacterium (Flavobacterium) indologenes. Antimicrob Agents Chemother 2000, 44:3028-3034.
13. Perilli M., Caporale B., Celenza G., Pellegrini C., Docquier J.D., Mezzatesta M., et al. Identification and characterization of a new metallo-beta-lactamase, IND-5, from a clinical isolate of Chryseobacterium indologenes. Antimicrob Agents Chemother 2007, 51:2988-2990.
14. Zeba B., De Luca F., Dubus A., Delmarcelle M., Simporé J., Nacoulma O.G., et al. IND-6, a highly divergent IND-type metallo-beta-lactamase from Chryseobacterium indologenes strain 597 isolated in Burkina Faso. Antimicrob Agents Chemother 2009, 53:4320-4326.
15. Yamaguchi Y., Takashio N., Wachino J., Yamagata Y., Arakawa Y., Matsuda K., et al. Structure of metallo-beta-lactamase IND-7 from a Chryseobacterium indologenes clinical isolate at 1.65-A resolution. J Biochem 2010, 147:905-915.
16. Performance standards for antimicrobial susceptibility testing: twenty-second informational supplement. CLSI document MI100-522 (ISBN 1-56238-785-5[Print]; ISBN 1-56238-783-3[Electronic]) 2012, Clinical and Laboratory Standards Institute, Wayne, PA, USA.
17. Aber R.C., Wennersten C., Moellering R.C. Antimicrobial susceptibility of flavobacteria. Antimicrob Agents Chemother 1978, 14:483-487.
18. Bloch K.C., Nadarajah R., Jacobs R. Chryseobacterium meningosepticum: an emerging pathogen among immunocompromised adults. Report of 6 cases and literature review. Medicine (Baltimore) 1997, 76:30-41.
19. Vaneechoutte M., Dijkshoorn L., Nemec A., Kämpfer P., Wauters G. Acinetobacter, Chryseobacterium, Moraxella, and other nonfermentative Gram-negative rods. Manual of clinical microbiology 2011, 714-738. ASM Press, Washington, DC. 10th ed. J. Versalovic (Ed.).
20. Lin Y.T., Chan Y.J., Chiu C.H., Lin M.L., Yu K.W., Wang F.D., et al. Tigecycline and colistin susceptibility of Chryseobacterium meningosepticum isolated from blood in Taiwan. Int J Antimicrob Agents 2009, 34:100-101.
21. Hsueh P.R., Teng L.J., Ho S.W., Hsieh W.C., Luh K.T. Clinical and microbiological characteristics of Flavobacterium indologenes infections associated with indwelling devices. J Clin Microbiol 1996, 34:1908-1913.
22. Hsueh P.R., Teng L.J., Yang P.C., Ho S.W., Hsieh W.C., Luh K.T. Increasing incidence of nosocomial Chryseobacterium indologenes infections in Taiwan. Eur J Clin Microbiol Infect Dis 1997, 16:568-574.
23. Pan H.J., Teng L.J., Chen Y.C., Hsueh P.R., Yang P.C., Ho S.W., et al. High protease activity of Chryseobacterium indologenes isolates associated with invasive infection. J Microbiol Immunol Infect 2000, 33:223-226.
24. Fraser S.L., Jorgensen J.H. Reappraisal of the antimicrobial susceptibilities of Chryseobacterium and Flavobacterium species and methods for reliable susceptibility testing. Antimicrob Agents Chemother 1997, 41:2738-2741.
25. Chou D.W., Wu S.L., Lee C.T., Tai F.T., Yu W.L. Clinical characteristics, antimicrobial susceptibilities, and outcomes of patients with Chryseobacterium indologenes bacteremia in an intensive care unit. Jpn J Infect Dis 2011, 64:520-524.
26. Kataoka D., Fujiwara H., Kawakami T., Tanaka Y., Tanimoto A., Ikawa S., et al. The indirect pathogenicity of Stenotrophomonas maltophilia. Int J Antimicrob Agents 2003, 22:601-606.
27. Hsueh P.R., Chang J.C., Teng L.J., Yang P.C., Ho S.W., Hsieh W.C., et al. Comparison of E test and agar dilution method for antimicrobial susceptibility testing of Flavobacterium isolates. J Clin Microbiol 1997, 35:1021-1023.